domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md

@@ -30,6 +30,18 @@ This has major implications: (1) the drug should benefit patients across the BMI
 
 ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss.
 
+### Additional Evidence (confirm)
+*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
+
+SELECT trial prespecified analysis (N=17,604) published in The Lancet November 2025 confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication.
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
+
+ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker) mediated 42.1% of CV benefit while body weight mediated only 19.5%. Joint mediation of all measured metabolic factors was 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% of benefit unexplained by adiposity or standard metabolic parameters. The convergence between this analysis (68.6% unexplained) and the Lancet prespecified analysis (67% weight-independent) from independent methodologies strengthens the anti-inflammatory mechanism hypothesis.
+
+
+
 
 Relevant Notes:
 - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]

inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md

@@ -7,9 +7,13 @@ date: 2025-11-01
 domain: health
 secondary_domains: []
 format: journal-article
-status: unprocessed
+status: enrichment
 priority: high
 tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mechanism, adiposity, MACE]
+processed_by: vida
+processed_date: 2026-03-30
+enrichments_applied: ["semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md", "semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -56,3 +60,12 @@ tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mec
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Closes active thread on GLP-1 CV mechanism; establishes weight-independence as the primary clinical finding; connects GLP-1 benefit to SDOH-generated inflammatory pathways
 EXTRACTION HINT: Focus on the 67-69% weight-independence figure and the hsCRP mediation (42.1%) — together these establish the anti-inflammatory mechanism. Extract as mechanism claim, not just efficacy claim. Consider whether this should be a divergence with the existing GLP-1 claim that frames the drug primarily through metabolic/weight-loss lens.
+
+
+## Key Facts
+- SELECT trial enrolled 17,604 adults ≥45 years with BMI ≥27 and pre-existing CVD but no diabetes at baseline
+- Semaglutide 2.4mg weekly reduced MACE (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% overall
+- Approximately 33% of MACE reduction was explained by early reductions in waist circumference
+- hsCRP mediation analysis showed 42.1% of benefit attributable to inflammation pathways
+- Body weight mediated 19.5% of cardiovascular benefit in ESC 2024 analysis
+- The Lancet prespecified analysis was published November 2025, led by John Deanfield (UCL)